Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$59.24 USD
-0.26 (-0.44%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $59.26 +0.02 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Price, Consensus and EPS Surprise
HALO 59.24 -0.26(-0.44%)
Will HALO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HALO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HALO
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
HALO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?
Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue?
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
Other News for HALO
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies
Interesting HALO Put And Call Options For November 15th
Halozyme cut to Neutral at J.P. Morgan on valuation
Five Below downgraded, DoorDash upgraded: Wall Street's top analyst calls
Halozyme just downgraded at JPMorgan, here's why